By Helena Smolak Idorsia shares fell after the company said it continues to look for funding, given that a recent sale of assets to Sosei Group and cost.
Shares of Idorsia Ltd (OTCMKTS:IDRSF – Get Free Report) have been given a consensus recommendation of “Strong Sell” by the six ratings firms that are currently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a sell recommendation and two have given a hold recommendation to the company. Several research […]
In the U.S. futures for the S&P 500 were down 0.2% and futures for the Dow Jones Industrial Average decreased 0.2%. Changes in futures do not necessarily.
^Ad hoc announcement pursuant to Art. 53 LR Aprocitentan, Idorsia's oral, dual endothelin receptor antagonist is currently under review with health authorities for the treatment of patients with resistant hypertension. Idorsia will pay Janssen a conditional consideration up to a total cap of.
In the U.S. futures for the S&P 500 were down 0.3% and futures for the Dow Jones Industrial Average decreased 0.2%. Changes in futures do not necessarily.